Prostacyclins, which play a major role in therapy of severe IPAH and HPAH, inhibit TGFβ1 signaling and enhance BMP/BMPR2 signaling [41, 42]. This evidence concerns the gene TGFB1 and idiopathic pulmonary arterial hypertension.